<DOC>
	<DOCNO>NCT01021436</DOCNO>
	<brief_summary>This study understand inhale form amikacin spread throughout human body eliminate body make sure give inhaled form Amikacin patient safe well tolerate</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Aerosolized Amikacin Intubated Mechanically-ventilated Patients With Nosocomial Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Amikacin</mesh_term>
	<criteria>Male female subject confirm pneumonia , define presence new progressive infiltrate ( ) chest radiograph presence gramnegative organism either culture Gram stain respiratory secretion . The subject must intubate mechanically ventilate expect remain least 3 day start study treatment . Subjects tracheostomy also eligible . Subjects compromise suppressed Immune system , severe hypoxemia , neutropenia , serum creatinine &gt; 2mg/dl chronic liver disease Had primary lung cancer another malignancy metastatic lung Were know suspect active tuberculosis , cystic fibrosis , acquire immunodeficiency syndrome , Pneumocystis carinii pneumonia Were receive immunosuppressive therapy , define chronic treatment know immunosuppressant medication Had body mass index â‰¥30 kg/m2 Had burn &gt; 40 % total body surface area Had know local systemic hypersensitivity amikacin aminoglycosides Had diagnosis endstage renal failure currently dialysis treatment Had serum albumin level &lt; 2 g/dL Screening Used amikacin route within 7 day start study treatment Had presence concomitant condition , opinion investigator , would preclude completion study evaluation make unlikely contemplated course therapy FollowUp could complete Had know respiratory colonization amikacinresistant gramnegative rod</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pneumonia</keyword>
	<keyword>Gram-negative bacteria</keyword>
</DOC>